Suppression of synuclein gamma inhibits the movability of endometrial carcinoma cells by PI3K/AKT/ERK signaling pathway

다국어 초록 (Multilingual Abstract)

Background Although overexpression of synuclein gamma (SNCG) has been reported in several cancers, few studies have been performed onSNCG in endometrial carcinomas.
Objective This study aimed to investigate the role of SNCG in the progression of endometrial carcinoma.
Methods The expression pattern and function ofSNCG gene were analyzed using the Gene Expression Omnibus (GEO) and Gene Set Enrichment Analysis (GSEA) datasets. Two vector types, containing either SNCG or negative control shRNAs, were used to evaluate cell proliferation, apoptosis, and metastasis using Cell Counting Kit 8, colony formation, fow cytometry, wound-healing, transwell, and invasion assays. The relative protein levels of N-cadherin, E-cadherin, vimentin, p-PI3K, PI3K, p-AKT, AKT, p-ERK, and ERK were determined by western bloting.
Results Our results revealed thatSNCG mRNA expression and SNCG protein levels in shRNA-treated SPEC2 cells were lower than in the negative control cells. Furthermore, cell proliferation, migration, and invasion were signifcantly inhibited in SNCG shRNA-treated cells, but apoptosis was increased. The results of western blot analysis indicated that SNCG silencing reduced the protein levels of N-cadherin, vimentin, p-PI3K, p-AKT, and p-ERK, but not those of total PI3K, AKT, and ERK.
Conclusions Therefore, shRNA-mediated suppression of SNCG inhibited SPEC2 cell proliferation, migration, and invasion, and promoted SPEC2 cell apoptosis, which was presumably accomplished via regulation of the PI3K/AKT/ERK signaling pathway.

참고문헌 (Reference)

1 Andrei Surguchov, "γ-Synuclein as a Cancer Biomarker: Viewpoint and New Approaches" Ivyspring International Publisher 1 : 1-3, 2016

2 Jingsong He, "siRNA-Mediated Suppression of Synuclein γ Inhibits MDA-MB-231 Cell Migration and Proliferation by Downregulating the Phosphorylation of AKT and ERK" 한국유방암학회 17 (17): 200-206, 2014

3 Clayton DF, "The synucleins : a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease" 21 : 249-254, 1998

4 Shi H, "The Latest Progress in Studies of Mitotic Checkpoint Gene BubR1" 7 : 1110-1112, 2007

5 Surgucheva I, "Synucleins in glaucoma : Implication of γ-synuclein in glaucomatous alterations in the optic nerve" 68 : 97-106, 2002

6 Bruening W, "Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary" 88 : 2154-2163, 2000

7 Mhawech-Fauceglia P, "Synuclein-gamma(SNCG)protein expression is associated with poor outcome in endometrial adenocarcinoma" 124 : 148-152, 2012

8 Morgan J, "Synuclein-gamma(SNCG)may be a novel prognostic biomarker in uterine papillary serous carcinoma" 114 : 293-298, 2009

9 Singh VK, "Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs" 67 : 626-633, 2007

10 Creutzberg CL, "Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma : multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma" 355 : 1404-1411, 2000

11 Jia T, "Stimulation of breast cancer invasion and metastasis by synuclein gamma" 59 : 742-747, 1999

12 Cirak Y, "Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer" 8 : 5345-5353, 2015

13 Altomare DA, "Perturbations of the AKT signaling pathway in human cancer" 24 : 7455-7464, 2005

14 Asati V, "PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents : structural and pharmacological perspectives" 109 : 314-341, 2016

15 Li Z, "Overexpression of synuclein-gamma in pancreatic adenocarcinoma" 101 : 58-65, 2004

16 Surgucheva I, "New α-and γ-synuclein immunopathological lesions in human brain" 2 : 132-132, 2014

17 Kato T, "New revised FIGO 2008 staging system for endometrial cancer produces better discrimination in survival compared with the 1988 staging system" 106 : 938-941, 2012

18 Guo J, "Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer" 121 : 1296-1305, 2007

19 Nakajima S, "N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma" 10 : 4125-4133, 2004

20 Polymeropoulos MH, "Mutation in the alpha-synuclein gene identifed in families with Parkinson’s disease" 276 : 2045-2047, 1997

21 Surguchov A, "International Review of Cell and Molecular Biology vol. 320" Academic Press 103-169, 2015

22 Ji H, "Identifcation of a breast cancer-specifc gene, BCSG1, by direct diferential cDNA sequencing" 57 : 759-764, 1997

23 Ahmad M, "Gamma-synuclein and the progression of cancer" 21 : 3419-3430, 2007

24 Ye Q, "Expression of gamma-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116" 15 : 5035-5043, 2009

25 Zhou J, "Expression of E-cadherin and vimentin in oral squamous cell carcinoma" 8 : 3150-3154, 2015

26 Yang YM, "Epithelial-to-mesenchymal transition in the development of endometriosis" 8 : 41679-41689, 2017

27 Orr JW Jr, "Endometrial cancer:is surgical staging necessary?" 13 : 408-412, 2001

28 Surgucheva IG, "Efect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells" 410 : 167-176, 2003

29 Ball HG, "Do we know the best therapy for early endometrial cancer?" 60 : 173-175, 1996

30 Thiery JP, "Complex networks orchestrate epithelialmesenchymal transitions" 7 : 131-142, 2006

31 Schaal K, "Alternative splicing of synuclein gamma in endometrial cancer : identifcation of a novel isoform" 6 : 22553-22563, 2015

32 Gehren AS, "Alterations of the apical junctional complex and actin cytoskeleton and their role in colorectal cancer progression" 3 : e1017688-, 2015

33 Spillantini MG, "Alpha-synuclein in Lewy bodies" 388 : 839-840, 1997

34 Lanciano RM, "Adjuvant treatment for endometrial cancer : who needs it?" 57 : 135-137, 1995

35 Gerard C, "A skeleton model for the network of cyclin-dependent kinases driving the mammalian cell cycle" 1 : 24-35, 2011

36 Keys HM, "A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma : a Gynecologic Oncology Group study" 92 : 744-751, 2004